Navigation Links
Helix BioPharma Corp. Announces Fiscal 2008 Results
Date:10/28/2008

Euro dollar appreciated against all currencies. The net assets in Europe consist mainly of cash and cash equivalents, denominated in Euro dollars and are used to fund clinical trials of the Topical Interferon Alpha-2b in Europe.

Impairment of intangible assets totaled $nil in fiscal 2008 and $1,332,000 in fiscal 2007. The Company believed future cash flows may not exceed the carrying value of its biochip technology and in fiscal 2007 recorded an impairment of its biochip technology.

Income tax expenses totaled $153,000 in fiscal 2008 and $105,000 in fiscal 2007. Income taxes are attributable to the Company's operations in Europe where royalty revenue remained flat on a year over year basis.

Liquidity and Capital Resources

Since inception, the Company has financed its operations from public and private sales of equity, the exercise of warrants and stock options, and, to a lesser extent, on interest income from funds available for investment, government grants, investment tax credits, and revenues from distribution, licensing and contract services. Since the Company does not have net earnings from its operations, the Company's long-term liquidity depends on its ability to access the capital markets, which depends substantially on the success of the Company's ongoing research and development programs.

At July 31, 2008, 2007 and 2006, the Company had cash and cash equivalents totaling $19,057,000, $11,379,000 and $4,392,000 respectively. The increase in cash and cash equivalents is the result of several rounds of private placements. In fiscal 2007, the Company completed a private placement issuing 3,650,000 units at $1.93 per unit, for gross proceeds of $7,044,500. Each unit consisted of one common share and one common share purchase warrant. The common share purchase warrants expired, unexercised on March 31, 2008. In fiscal 2008, the Company completed another private placement issuing 10,040,000 common shares at $1.68 per common sha
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma Closes $11.4 Million Private Placement
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
6. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
7. Helix BioPharma reports Q2 2008 highlights, financial results
8. Helix BioPharma shareholders vote in favour of management
9. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Helix BioPharma announces Q1 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, Inc. ... products for skin and hair rejuvenation, has announced ... agency of record for investor relations and strategic ... our distribution, sales and diversification strategies – and ... and prospective shareholders," stated Ali Kharazmi CEO of ...
(Date:2/26/2015)... 2015 Already well respected for accuracy, ... expanding its Length Gauge offerings with new variants of ... , Specifically, HEIDENHAIN’s pencil probe-style SPECTO length gauge series ... Two new 1Vpp, 12mm stroke length variants of the ... is a variant with a weak spring, 0.4N of ...
(Date:2/26/2015)... JUPITER, Fla. , Feb. 26, 2015 /PRNewswire/ ... biotechnology company whose patented and proprietary technologies are ... other proteins for the bioenergy, bio-based chemical, biopharmaceutical ... will report its financial results for year ending ... March 11, 2015 and will host a conference ...
(Date:2/26/2015)...  Epic Sciences announced today that President and CEO ... 35th Annual Cowen and Company Health Care Conference on Wednesday, ... 3rd Floor. The conference will be held at the ... Epic is developing diagnostic tests of high clinical utility ... that occur during the course of cancer treatments. From ...
Breaking Biology Technology:NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2
... Sept. 1, 2011 Asmacure Ltee, a clinical-stage ... receptor agonists for the treatment of asthma and ... Driscoll will present at the 2011 BioPharm America ... provide an overview of Asmacure,s nicotinic acetylcholine receptor ...
... Sept. 1, 2011 Veracyte, Inc., a molecular diagnostics ... announced that new data from researchers at Johns Hopkins ... its Afirma® Gene Expression Classifier for clarifying inconclusive results ... improve patient care and save the healthcare system money. ...
... 1, 2011 The age-old fascination with machines ... fiction literature and cinema, mainly because authors and ... robots" since none had been built yet. According ... largest professional technical association, the distinction between science ...
Cached Biology Technology:Asmacure Ltee to Present at the 2011 BioPharm America Conference 2New Data Suggest Veracyte's Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results 2New Data Suggest Veracyte's Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results 3Mind-Controlled Bionic Limbs Holding Promise, and the Demand is Growing say IEEE Experts 2Mind-Controlled Bionic Limbs Holding Promise, and the Demand is Growing say IEEE Experts 3Mind-Controlled Bionic Limbs Holding Promise, and the Demand is Growing say IEEE Experts 4
(Date:2/5/2015)... , Jan. 27, 2015   Marvin ... globally deployed, innovative test solutions for military, ... delivery of its TS-323 GENASYS Test ... Company (LMSSC). GENASYS is a high-performance PXI-based ... mission-critical applications that require performance functional testing. ...
(Date:2/5/2015)... Feb. 3, 2015 Despite a lack ... industries such as consumer electronics, automotive, storage and ... mount technology (SMT) screen printers. Innovations in electronics ... will push the adoption curve up. Meanwhile, sale ... as glue dispensers are indispensable in the production ...
(Date:1/22/2015)... Hall E -   EyeLock Inc. , a market leader ... its EyeLock ID technology integrated in a 3D printed automobile ... Ridge National Laboratory (ORNL) at the 2015 North ... is being used to validate the driver and authorize the ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... uncanny ability to detect electrical signals while hunting and ... those electrosensory powers to the same type of embryonic ... features in humans. , The discovery, reported by University ... & Development, identifies neural crest cells, which are common ...
... Studies have identified an important circuit in the spinal ... muscles contract and relax. Their findings mark an important ... movements - one of the main obstacles in developing ... circuits are important and understanding how they control the ...
... Comparative Functional Genomics and the University of California, Berkeley ... of microRNA (miRNA) targets in the animal model organism, ... (mRNA) in a specific section, called 3'UTR, and are ... were confirmed through the development of a novel in ...
Cached Biology News:UF scientists trace origin of shark's electric sense 2UF scientists trace origin of shark's electric sense 3Salk researchers make fast strides towards understanding how our body controls walking 2Biologists develop genome-wide map of miRNA-mRNA interactions 2
... DASGIP Overhead Drive for individual and ... for flexible agitation of DASGIP vessels, featuring ... impellers. ,Up to 16 overhead drives ... DASGIP Cultivation Systems fedbatch-pro® and cellferm-pro® for ...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
SDS-OutT Precipitation Reagent...
Biology Products: